Dr. Nita Patel, Director of Antibody discovery and Vaccine advancement, raises a vial with a prospective coronavirus, COVID-19, vaccine at Novavax laboratories in Gaithersburg, Maryland on March 20, 2020, among the laboratories establishing a vaccine for the coronavirus, COVID-19.
Andrew Caballero-Reynolds | AFP | Getty Images
Novavax on Tuesday postponed the start of a late-stage U.S. trial of its speculative coronavirus vaccine by approximately a month to the end of November, mentioning hold-ups in scaling up the production procedure.
The U.S.-based drug designer stated information from a different stage 3 trial being carried out in Britain was anticipated by the very first quarter of 2021 and might be the basis for regulative approval, sending its shares up 3.4% in early trading.
Data from an early-to-mid phase or stage 2 trial of the vaccine is now anticipated on Friday, the business stated. Early-phase information had actually revealed the vaccine produced high levels of antibodies versus the unique coronavirus.
A handful of business, consisting of bigger competitors Pfizer and AstraZeneca, have actually started evaluating their vaccines in late-stage trials, though none is yet to win regulative approvals.
Novavax in August stated it will provide 60 million dosages of its coronavirus vaccine prospect to the UK from as early as the very first quarter of 2021.
The business is likewise preparing to provide 100 million dosages to the United States by January after it was granted $1.6 billion for its prospective vaccine and has actually likewise signed supply arrangements with Canada and Japan.